Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDel Announces Pre-Clinical Data on Cyto-111 as Antidote to Botulinum Neurotoxin (BoNT) .
CytoDel IncJanuary 7, 2021 GMT
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection
Supports the Development of New Approaches to Treat Multiple Neurological Diseases
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) CytoDel, Inc. (“CytoDel” or “the Company”), a privately-held corporation, today announces the publication of preclinical data on the Company’s lead product, Cyto-111, in the peer-reviewed journal,
Science Translational Medicine. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found here.
E-Mail
New York City, January 6, 2021 - CytoDel, Inc. ( CytoDel or the Company ), a privately-held corporation, today announces the publication of preclinical data on the Company s lead product, Cyto-111, in the peer-reviewed journal,
Science Translational Medicine. The complete text of the article titled, Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism, can be found here.
Cyto-111 was conceived, expressed and purified in the laboratory of Konstantin Ichtchenko, Ph.D., NYU Grossman School of Medicine, Department of Biochemistry and Molecular Pharmacology, who was a principal investigator in the study, which was supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH).